Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia LoRusso

Showing results (91-100 of 164) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancerAung Naing, Razelle Kurzrock, Angelika Burger, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studySuresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumorsAlain C Mita, Chris H Takimoto, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumorsElisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Investigational New Drugs|July 18, 2016
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsLee S Rosen, Patricia LoRusso, Wen Wee Ma, et al.
Frontiers in Oncology|February 17, 2025
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Frontiers in Oncology|November 13, 2024
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Pageof 17

Showing results (91-100 of 164) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancerAung Naing, Razelle Kurzrock, Angelika Burger, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studySuresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumorsAlain C Mita, Chris H Takimoto, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumorsElisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Investigational New Drugs|July 18, 2016
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsLee S Rosen, Patricia LoRusso, Wen Wee Ma, et al.
Frontiers in Oncology|February 17, 2025
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Frontiers in Oncology|November 13, 2024
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Pageof 17